机构：[1]Department of Hepatic Oncology, Zhongshan Hospital of Fudan University, Shanghai,China[2]Deapartment of Liver Surgery, Zhongshan Hospital of Fudan University,Shanghai, China[3]Digestive Oncology Department, The 5th Medical Center of PLAGeneral Hospital, Beijing, China[4]Department of Internal Medicine, Harbin MedicalUniversity Cancer Hospital, Harbin, China[5]Oncological Internal Medicine, NantongTumor Hospital, Nantong, China[6]Internal Medicine Oncology, Henan ProvincialPeople’s Hospital, Zhengzhou, China[7]Hepatobiliary Surgery, The First Affiliated Hospitalof Chongqing Medical University, Chongqing, China重庆医科大学附属第一医院[8]Department of Oncology,Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, China[9]Abdominal Tumor Department, West China Hospital, Sichuan University, Chengdu,China四川大学华西医院[10]Treatment and Research Center For Liver Cancer Department Two, The FifthMedical Center of PLA Ceneral Hospital, Beijing, China[11]Hepatobiliary Surgery, SunYat-sen Memorial Hospital Sun Yat-sen University, Guangzhou, China中山大学附属第二医院[12]Departmentof Interventional Therapy, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[13]Tumors ofLiver, Nan Fang Hospital, Guangzhou, China[14]Oncology Department, The SecondHospital of Anhui Medical University, Hefei, China[15]Medical Science and StrategyOncology, Innovent Biologics, Inc., Suzhou, China[16]Statistical Department, InnoventBiologics, Inc., Suzhou, China
第一作者机构：[1]Department of Hepatic Oncology, Zhongshan Hospital of Fudan University, Shanghai,China
推荐引用方式(GB/T 7714)：
Ren Z.,Fan J.,Xu J.,et al.Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2[J].ANNALS OF ONCOLOGY.2020,31:S1287-S1287.doi:10.1016/j.annonc.2020.10.134.
APA：
Ren, Z.,Fan, J.,Xu, J.,Bai, Y.,Xu, A....&Zhou, H..(2020).Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2.ANNALS OF ONCOLOGY,31,
MLA：
Ren, Z.,et al."Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2".ANNALS OF ONCOLOGY 31.(2020):S1287-S1287
医学